Joseph Markowitz, MD, PhD
Researcher

Joseph Markowitz, MD, PhD

Academic Rank: Assistant Member

Overview

Discipline

    • Cutaneous Oncology
    • Immunology
    • Immunology

Education & Training

    • University of Maryland Baltimore, MD, PhD - Biochemistry
    • The Ohio State University, Resident - Internal Medicine
    • The Ohio State University, Fellow - Medical Oncology
    • The Ohio State University, Research Fellow
    • The Ohio State University, Fellow - Advanced Medical Oncology
Research

Dr. Markowitz's research interest is in studying immune suppressor cells, their role in the development of melanoma, and means of inhibiting their actions. He is a translational researcher striving to translate the knowledge gained in the laboratory via immune-based and traditional biochemical approaches to the clinic.

Publications

  • Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson Iii WE. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immun. 2017 Nov;66(11):1437-1447. Pubmedid: 28688082. Pmcid: PMC5647220.
  • Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4(+) T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2017 Nov;7(1):15424. Pubmedid: 29133913.
  • Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, Terando A, Markowitz J, Agnese D, Payne P, Carson WE. Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinform Biol Insights. 2017 Feb;11. Pubmedid: 28469417. Pmcid: PMC5345922.
  • Yarlagadda K, Hassani J, Foote IP, Markowitz J. The role of nitric oxide in melanoma. Biochim Biophys Acta. 2017 Dec;1868(2):500-509. Pubmedid: 28963068.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017 Aug;10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE. MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther. 2016 Sep;9:5931-5941. Pubmedid: 27729802. Pmcid: PMC5047719.
  • Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, Blachly J, Walker C, Eisfeld AK, de la Chapelle A, Carson WE. Structural characterization of NRAS isoform 5. Protein Sci. 2016 May;25(5):1069-1074. Pubmedid: 26947772. Pmcid: PMC4838646.
  • Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec;4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
  • Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Nole TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016 Dec;7(49):81172-81186. Pubmedid: 27783987. Pmcid: PMC5348384.
  • Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Zhu J, Markowitz J, Carson WE, Basu S, Bai XF. A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. J Immunol. 2016 Aug;197(4):1489-1497. Pubmedid: 27385779. Pmcid: PMC4975953.
  • Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, Carson WE. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immun. 2015 Feb;64(2):149-159. Pubmedid: 25305035. Pmcid: PMC4504424.
  • Lankenau MA, Patel R, Liyanarachchi S, Maharry SE, Hoag KW, Duggan M, Walker CJ, Markowitz J, Carson WE, Eisfeld AK, de la Chapelle A. MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci U S A. 2015 Dec;112(49):E6744-E6751. Pubmedid: 26582795. Pmcid: PMC4679059.
  • Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A. 2014 Mar;111(11):4179-4184. Pubmedid: 24586049. Pmcid: PMC3964043.
  • Dhar A, Mallick S, Ghosh P, Maiti A, Ahmed I, Bhattacharya S, Mandal T, Manna A, Roy K, Singh S, Nayak DK, Wilder PT, Markowitz J, Weber D, Ghosh MK, Chattopadhyay S, Guha R, Konar A, Bandyopadhyay S, Roy S. Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptide. Biopolymers. 2014 Jul;102(4):344-358. Pubmedid: 24839139. Pmcid: PMC4107132.
  • Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother. 2014 Jan;37(1):55-62. Pubmedid: 24316557. Pmcid: PMC4174542.
  • Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Sci Signal. 2014 Apr;7(321):ra36. Pubmedid: 24736457. Pmcid: PMC4165404.
  • Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013 Jul;1:10. Pubmedid: 24829747. Pmcid: PMC4019895.
  • Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013 Jul;140(1):13-21. Pubmedid: 23828498. Pmcid: PMC3773691.
  • Markowitz J, Carson WE. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta. 2013 Jan;1835(1):100-109. Pubmedid: 23123827. Pmcid: PMC3670606.
  • Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep;15(18):5895-5901. Pubmedid: 19737952. Pmcid: PMC2774354.
  • Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont). 2008 Oct;5(10):29-36. Pubmedid: 19724721. Pmcid: PMC2695757.
  • Markowitz J, MacKerell AD, Weber DJ. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem. 2007 Jun;7(6):609-616. Pubmedid: 17584159.
  • Wright NT, Varney KM, Ellis KC, Markowitz J, Gitti RK, Zimmer DB, Weber DJ. The three-dimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy. J Mol Biol. 2005 Oct;353(2):410-426. Pubmedid: 16169012.
  • Markowitz J, Rustandi RR, Varney KM, Wilder PT, Udan R, Wu SL, Horrocks WD, Weber DJ. Calcium-binding properties of wild-type and EF-hand mutants of S100B in the presence and absence of a peptide derived from the C-terminal negative regulatory domain of p53. Biochemistry-Us. 2005 May;44(19):7305-7314. Pubmedid: 15882069.
  • Markowitz J, Mackerell AD, Carrier F, Charpentier TH, Weber DJ. Design of Inhibitors for S100B. Curr Top Med Chem. 2005;5(12):1093-1108. Pubmedid: 16248785.
  • Markowitz J, Chen I, Gitti R, Baldisseri DM, Pan Y, Udan R, Carrier F, MacKerell AD, Weber DJ. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J Med Chem. 2004 Oct;47(21):5085-5093. Pubmedid: 15456252.
  • Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004 Aug;279(32):34071-34077. Pubmedid: 15178678.
  • Lee ME, Markowitz J, Lee JO, Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 2002 Oct;530(1-3):53-58. Pubmedid: 12387865.